New PSA test examines protein structures to detect prostate cancers

A promising new test is detecting prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein, according to Cleveland Clinic research presented today at the American Urological Association annual meeting. The study — part of an ongoing multicenter prospective clinical trial — found that the IsoPSATM test can also differentiate between high-risk and low-risk disease, as well as benign conditions. Although widely used, the current PSA test relies on detection strategies that have poor specificity for cancer — just 25 percent of men who have a prostate biopsy due to an elevated…
View More/Source Article